NEW YORK (GenomeWeb News) — Invitrogen and Progenitor Cell Therapy today said they will co-develop and -market Invitrogen’s media and cell separation technologies, PCT said today.
The agreement will include marketing, co-referrals, joint proposals, and technical consulting around Invitrogen’s Dynabeads and Dynabeads ClinExVivo, which are ex vivo T-cell and immune-functioning technologies.
PCT specializes in cell manufacturing and consulting services that include “regulatory, financial, technical process and quality systems strategies,” the company said.
Invitrogen’s Dynal Bead Based Separation Group Director Oystein Amellem said PCT’s experience with Dynabeads and with “various expansion and media culture systems” is valuable to Invitrogen for “ongoing product development, product testing and validation, as well as customized technical integration and implementation of services. … ”
PCT’s development and manufacturing model “will be critical to the successful commercialization of many cell therapy products,” Amellem added.
PCT Chief Technology Officer Stewart Craig said partnerships with companies offering popular platforms such as Invitrogen’s are important to PCT’s strategy to offer integrated products for development because it positions the company to better help its customers develop and market their cell-based products.
Financial terms of the agreement were not released.